VRTX - VERTEX PHARMACEUTICALS INC / MA
IEX Last Trade
408.09
-0.155 -0.038%
Share volume: 17,664
Last Updated: Fri 27 Dec 2024 08:30:17 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$408.24
-0.16
-0.04%
Fundamental analysis
46%
Profitability
67%
Dept financing
7%
Liquidity
62%
Performance
30%
Performance
5 Days
0.86%
1 Month
-12.68%
3 Months
-12.11%
6 Months
-12.79%
1 Year
-0.12%
2 Year
43.04%
Key data
Stock price
$408.09
DAY RANGE
$404.74 - $410.65
52 WEEK RANGE
$396.14 - $519.88
52 WEEK CHANGE
$0.46
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
Company detail
CEO: Reshma Kewalramani
Region: US
Website: vrtx.com
Employees: 4,800
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: vrtx.com
Employees: 4,800
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial.
Recent news